Renowned Thoracic Surgeon Enhances Mesothelioma Care in FL
Dr. Rodney Landreneau is joining the renowned Thoracic Surgical Program at Tampa General Hospital. He spent decades caring for patients with pleural mesothelioma and lung cancer patients in Western Pennsylvania at the University of Pittsburgh and Penn Highlands Healthcare. He’s now moved more than 1,000 miles to help augment Tampa General Hospital Cancer Institute’s successful patient care.
Landreneau has nearly 40 years of experience treating malignant pleural mesothelioma and lung cancer, as well as benign and malignant diseases of the esophagus. An internationally recognized scientific investigator in the treatme...
Source: Asbestos and Mesothelioma News - February 26, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Cancer Center Doctors/Specialists Mesothelioma Treatment Source Type: news
Pegargiminase + Chemo Increases Survival Rate in Nonepithelioid Pleural Mesothelioma
FRIDAY, Feb. 23, 2024 -- For patients with nonepithelioid pleural mesothelioma, pegargiminase plus chemotherapy is associated with improved survival versus placebo plus chemotherapy, according to a study published online Feb. 15 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 23, 2024 Category: Pharmaceuticals Source Type: news
New Drug to Treat Mesothelioma Hailed as a Major Breakthrough
ADI-PEG20 or pegargiminase is being hailed as the first drug of its kind to be incorporated successfully with chemotherapy in 20 years. Researchers say this new drug could bring hope to thousands of mesothelioma survivors and their families.
The drug blocks the cancer’s food supply, ensuring the disease can’t spread. It prevents cancer cells from absorbing the amino acid arginine from the bloodstream. Arginine helps the body build protein.
Mesothelioma cells are deficient in a protein called ASS1, which allows cells to create their own arginine. If the cancer cells can’t get arginine from blood, the...
Source: Asbestos and Mesothelioma News - February 21, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
FDA Fast Tracks UV1 Vaccine Combo for Mesothelioma
The U.S. Food and Drug Administration granted fast-track designation to a new therapeutic cancer vaccine. The approval is for UV1 in combination with the immunotherapy drugs Opdivo (nivolumab) and Yervoy (ipilimumab) to manage malignant pleural mesothelioma that can’t be managed with surgery.
Therapeutic cancer vaccines, unlike preventive vaccines, treat existing cancers. Fast Track expedites the development of drug reviews for severe conditions. This way, the FDA can bring essential new drugs to patients earlier. With this designation, UV1 drug-maker Ultimovacs ASA will interact more frequently with the FDA dur...
Source: Asbestos and Mesothelioma News - February 21, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
Breakthrough New Drug ‘Starves’ Cancer Caused By Asbestos
Mesothelioma is almost always caused by exposure to asbestos in work trades such as construction. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 20, 2024 Category: Pharmaceuticals Authors: Victoria Forster, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Arginine Starvation Boosts OS in Mesothelioma
(MedPage Today) -- First-line chemotherapy plus an investigational arginine-depleting agent improved survival in nonepithelioid pleural mesothelioma compared with chemotherapy alone, a randomized trial showed.
For the study's primary endpoint... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 16, 2024 Category: Hematology Source Type: news
Breakthrough for hard-to-treat cancer as scientists hail 'truly wonderful' new drug
Academics in London said the new drug is the first of its type for mesothelioma in 20 years. Mesothelioma is a type of cancer usually linked to asbestos exposure. (Source: the Mail online | Health)
Source: the Mail online | Health - February 15, 2024 Category: Consumer Health News Source Type: news
Drug offers ‘wonderful’ breakthrough in treatment of asbestos-linked cancer
Medicine used alongside chemotherapy in trials quadrupled three-year survival rates for mesotheliomaScientists have developed a drug to treat mesothelioma, a notoriously hard-to-treat cancer linked to asbestos, in the biggest breakthrough in two decades.Thousands of people are diagnosed with the disease globally every year, which tends to develop in the lungs and ismainly caused by exposure to asbestos at work. It is aggressive and deadly, and has one of the world ’s worst cancer survival rates.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - February 15, 2024 Category: Science Authors: Andrew Gregory Health editor Tags: Cancer research Health Medical research Science Society Queen Mary, University of London UK news Source Type: news
New Treatment Brings Hope for Rare, Deadly Cancer Linked to Asbestos, Malignant Mesothelioma
THURSDAY, Feb. 15, 2024 -- Mick worked in a factory boiler room in the 1970s, where he was exposed to asbestos.
He didn’t think much of it until 2018, when he began to feel ill and dropped more than 40 pounds.
The diagnosis: malignant... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 15, 2024 Category: General Medicine Source Type: news
Early Detection Tests for Mesothelioma Are in Development
Scientists in Australia are developing early detection tests for mesothelioma. The Asbestos and Dust Diseases Research Institute’s new test could potentially save lives. According to ADDRI’s academic and research director Dr. Anthony Linton, the tests will be similar to PCR tests already in use to detect COVID-19.
These new tests can find small amounts of DNA that cause disease. The PCR method, used since the 1980s, allows DNA samples to be studied in a higher level of detail. PCR is the tech behind the beginning of the 1990 Human Genome Project to identify and map human DNA.
“We have identified a...
Source: Asbestos and Mesothelioma News - February 13, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Asbestos Exposure Clinical Trials/Research/Emerging Treatments Doctors/Specialists Mesothelioma Source Type: news
U.S. Nuclear Missile Bases Under Investigation for Cancer Risks
The U.S. Air Force is investigating nuclear missile bases for asbestos and other potentially cancer-causing materials. The Associated Press recently revealed that the issues date as far back as the late 1980s. Reports prove that the Air Force has been aware of toxic chemicals at nuclear launch silos for decades.
Air Force documents reveal details about several leaks and spills at missile bases across the country over the course of several years. Records describe repeated spills or leaks affecting service members working at the sites. The documents reveal internal reports of asbestos leaks at missile silos in 1989, as ...
Source: Asbestos and Mesothelioma News - February 9, 2024 Category: Environmental Health Authors: Amy Edel Tags: Air Force Asbestos (general) Asbestos Exposure Cancer (Non-Meso) Source Type: news
Nonprofit Teams With Firefighter Union for Asbestos Ban Campaign
The Asbestos Disease Awareness Organization is teaming with the International Association of Fire Fighters on a new anti-asbestos campaign. In a continued push toward a national ban of the toxic mineral, the organizations have created a 120 foot high and 84 foot wide billboard in New York City’s Times Square.
A firefighter in full gear is the focal point of the advertisement. Written on the picture are the words: “Firefighters Face Risk.” Under that in large red letters it reads: “Ban Asbestos Now.”
The message is expected to make 1.5 million impressions a day and will be seen 4 times every hour for 1...
Source: Asbestos and Mesothelioma News - February 6, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Asbestos (general) Asbestos Exposure Awareness/Advocacy Mesothelioma Support/Support Groups/Organizations Source Type: news
Phase I Trial Improves Mesothelioma Survival More Than 200%
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
Early Mesothelioma Vaccine Testing Shows Survival Gains
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Sean Marchese Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
Early Mesothelioma Vaccine Testing Shows Promise
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Sean Marchese Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
